Literature DB >> 31235038

Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect.

Giacomo Nuvola1, Filippo Gustavo Dall'Olio2, Barbara Melotti2, Francesca Sperandi2, Andrea Ardizzoni2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31235038     DOI： 10.1016/j.jtho.2019.02.027

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma.

Authors:  Saori Ikebe; Ryohei Amiya; Seigo Minami; Shoichi Ihara; Yoshiharu Higuchi; Kiyoshi Komuta
Journal:  Int Cancer Conf J       Date:  2020-10-15

Review 2.  Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.

Authors:  Kalyan R Chitturi; Ethan A Burns; Ibrahim N Muhsen; Kartik Anand; Barry H Trachtenberg
Journal:  Curr Oncol Rep       Date:  2022-02-22       Impact factor: 5.075

3.  Hypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review.

Authors:  Zhiwei Tang; XiuHai Ji; Guanghui Zhou; Ruhua Chen; Yan Fen; Hui Ding
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.